Carmell CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
CTCX
Carmell CORPLongevity Health Holdings, Inc. filed its Q2 2026 10-Q, revealing a significant net loss, declining sales, and substantial doubt about its ability to continue as a going concern.
CTCX
Carmell CORPLongevity Health Holdings, Inc. reported a reduced net loss for Q3 2025, driven by the Elevai acquisition, but faces Nasdaq delisting and significant going concern doubts while pursuing a merger with THPlasma.
CTCX
Carmell CORPLongevity Health Holdings, Inc. reported significant revenue growth in Q2 2025, driven by the Elevai acquisition, while announcing a definitive merger agreement with True Health Inc. and addressing ongoing financial challenges.
CTCX
Carmell CORPLongevity Health Holdings announces its Q1 2025 financial results, highlighting the Elevai Skincare acquisition and ongoing efforts to regain Nasdaq compliance amidst a proposed merger with 20/20 Biolabs.
CTCX
Carmell CORPCarmell Corporation's Q3 2024 results show a strategic shift towards cosmetic skincare, reduced R&D spending, and ongoing efforts to manage liquidity amidst a net loss.
CTCX
Carmell CORPCarmell Corporation's Q2 2024 report highlights a strategic shift towards cosmetic skincare and haircare, alongside the divestiture of AxoBio.
CTCX
Carmell CORPCarmell Corporation reported a net loss for Q1 2024, while strategically divesting AxoBio and shifting focus to its aesthetic product line.